Form 4: Biogen Inc. Executive Priya Singhal Reports Stock Sale

Priya Singhal, Head of Development at Biogen Inc., reported the sale of 3,806 shares of common stock on May 19, 2025.

Summary

• Priya Singhal, Head of Development at Biogen Inc., filed a Form 4 with the SEC.
• The form reports a transaction that occurred on May 19, 2025.
• Singhal sold 3,806 shares of Biogen Inc. common stock at a price of $126.25 per share.
• Following the transaction, Singhal beneficially owns 5,427.1428 shares of Biogen Inc. common stock.
• The report also notes that 166.6667 shares were acquired under the Biogen Inc. employee stock purchase plan on March 31, 2025.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a stock sale by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a sale of shares by a high-ranking executive, which could be for a variety of personal financial reasons and doesn't necessarily reflect a negative outlook on the company.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to have a significant impact on other stakeholders.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Sale, Biogen, BIIB, Singhal, SEC